Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADIPOQ antisense RNA 1 (ADIPOQ-AS1) is a long non-coding RNA (lncRNA) that overlaps with the ADIPOQ (adiponectin) gene and acts primarily as a post-transcriptional regulator of ADIPOQ expression[4][6]. It does not encode a protein and is classified as an antisense lncRNA[4][5]. Genome-wide association studies indicate that genetic variation at the ADIPOQ locus can influence the expression of ADIPOQ-AS1, which modulates adiponectin biology and potentially regulates adipogenic and metabolic processes in adipose tissue[2][4]. Functional studies suggest that ADIPOQ-AS1 can inhibit adipogenesis by forming a duplex with ADIPOQ mRNA, leading to suppression of ADIPOQ translation and fat cell differentiation[6]. It is not currently considered a classical therapeutic target such as a receptor, enzyme, or transporter, nor are any drugs directly known to target it. ADIPOQ-AS1 may play a disease role as a regulator in conditions like adiponectin deficiency, but its potential as a biomarker or drug target requires further study[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADIPOQ antisense RNA 1 (ADIPOQ-AS1).